WO2006086978A3 - Verwendung deuterierter n-[2-(5-methoxy-1h-indol-3-yl)-ethyl]acetamide und deren pharmazeutisch verträglicher salze sowie diese verbindungen enthaltende arzneimittel - Google Patents

Verwendung deuterierter n-[2-(5-methoxy-1h-indol-3-yl)-ethyl]acetamide und deren pharmazeutisch verträglicher salze sowie diese verbindungen enthaltende arzneimittel Download PDF

Info

Publication number
WO2006086978A3
WO2006086978A3 PCT/DE2006/000317 DE2006000317W WO2006086978A3 WO 2006086978 A3 WO2006086978 A3 WO 2006086978A3 DE 2006000317 W DE2006000317 W DE 2006000317W WO 2006086978 A3 WO2006086978 A3 WO 2006086978A3
Authority
WO
WIPO (PCT)
Prior art keywords
acetamides
indol
methoxy
ethyl
deuterated
Prior art date
Application number
PCT/DE2006/000317
Other languages
English (en)
French (fr)
Other versions
WO2006086978A2 (de
Inventor
Moritz Hillgenberg
Rudolf-Giesbert Alken
Original Assignee
Birds Pharma Gmbh Berolina Inn
Moritz Hillgenberg
Rudolf-Giesbert Alken
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Birds Pharma Gmbh Berolina Inn, Moritz Hillgenberg, Rudolf-Giesbert Alken filed Critical Birds Pharma Gmbh Berolina Inn
Publication of WO2006086978A2 publication Critical patent/WO2006086978A2/de
Publication of WO2006086978A3 publication Critical patent/WO2006086978A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Die vorliegende Erfindung betrifft die Verwendung deuterierter N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]acetamide, oder deren pharmazeutisch verträglichen Salzen zur Prophylaxe, Behandlung oder Steuerung einer Störungen, Er-krankung oder biologischen Funktion, die mit einem relativen Melatoninmangel in Zusammenhang steht und/oder durch die Gabe von Melatonin behandelt beziehungsweise beeinflusst werden kann, unter der Bedingung, dass es sich bei der Erkrankung oder Störung nicht um Störungen im Rahmen einer manischen Depression handelt. Ein weiterer Gegenstand der Erfindung ist die Verwendung deuterierter N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]acetamide, oder deren pharmazeutisch verträglicher Salze zur Herstellung eines Arzneimittels. Weiterhin wird ein Arzneimittel offenbart, das deuterierter N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]acetamide, oder deren pharmazeutisch verträgliche Salze enthält.
PCT/DE2006/000317 2005-02-17 2006-02-16 Verwendung deuterierter n-[2-(5-methoxy-1h-indol-3-yl)-ethyl]acetamide und deren pharmazeutisch verträglicher salze sowie diese verbindungen enthaltende arzneimittel WO2006086978A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005008312.9 2005-02-17
DE102005008312A DE102005008312A1 (de) 2005-02-17 2005-02-17 Verwendung deuterierter N-[2-(5-Methoxy-1H-indol-3-yl)-ethyl]acatamide und deren pharmazeutisch verträglicher Salze sowie diese Verbindungen enthaltende Arzneimittel

Publications (2)

Publication Number Publication Date
WO2006086978A2 WO2006086978A2 (de) 2006-08-24
WO2006086978A3 true WO2006086978A3 (de) 2006-12-07

Family

ID=36650183

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2006/000317 WO2006086978A2 (de) 2005-02-17 2006-02-16 Verwendung deuterierter n-[2-(5-methoxy-1h-indol-3-yl)-ethyl]acetamide und deren pharmazeutisch verträglicher salze sowie diese verbindungen enthaltende arzneimittel

Country Status (2)

Country Link
DE (1) DE102005008312A1 (de)
WO (1) WO2006086978A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2081893B1 (de) * 2006-10-19 2011-03-23 Auspex Pharmaceuticals, Inc. Substituierte indole
JP4642134B2 (ja) * 2007-05-01 2011-03-02 コンサート ファーマシューティカルズ インコーポレイテッド ナフチル（エチル）アセトアミド
US8637524B2 (en) 2009-07-28 2014-01-28 Auspex Pharmaceuticals, Inc Pyrimidinone inhibitors of lipoprotein-associated phospholipase A2
US9512104B2 (en) 2009-07-28 2016-12-06 Auspex Pharmaceuticals, Inc. Quinolone inhibitors of lipoprotein-associated phospholipase A2
US8575348B2 (en) 2009-07-28 2013-11-05 Auspex Pharmaceuticals, Inc Quinolone inhibitors of lipoprotein-associated phospholipase A2
CA3177454A1 (en) 2020-05-19 2021-11-25 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083144A1 (en) * 1998-11-13 2002-10-24 Rupert Charles Bell Method of treatment using deuterium compounds
US20030139440A1 (en) * 1997-09-05 2003-07-24 Selvaraj Naicker Deuterated rapamycin compounds, method and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH673074B5 (de) * 1988-06-30 1990-08-15 Ebauchesfabrik Eta Ag
US6638963B1 (en) * 1990-12-04 2003-10-28 Oregon Health And Science University Methods for treating circadian rhythm disorders
US5654325A (en) * 1993-11-18 1997-08-05 Eli Lilly And Company Melatonin derivatives for use in treating sleep disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030139440A1 (en) * 1997-09-05 2003-07-24 Selvaraj Naicker Deuterated rapamycin compounds, method and uses thereof
WO2002083144A1 (en) * 1998-11-13 2002-10-24 Rupert Charles Bell Method of treatment using deuterium compounds

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ALMEIDA EDUARDO A ET AL: "Synthesis of internal labeled standards of melatonin and its metabolite N1-acetyl-N2-formyl-5-methoxykynuramine for their quantification using an on-line liquid chromatography-electrospray tandem mass spectrometry system.", JOURNAL OF PINEAL RESEARCH, vol. 36, no. 1, January 2004 (2004-01-01), pages 64 - 71, XP002391398, ISSN: 0742-3098 *
DMITREVSKAYA ET AL: "Melatonin labeled with hydrogen isotopes", ZHURNAL OBSHCHEI KHIMII, vol. 58, no. 7, 1988, pages 1621 - 1625, XP009069651 *
ERIKSSON K ET AL: "Quantification of melatonin in human saliva by liquid chromatography-tandem mass spectrometry using stable isotope dilution", JOURNAL OF CHROMATOGRAPHY B: BIOMEDICAL SCIENCES & APPLICATIONS, ELSEVIER, AMSTERDAM, NL, vol. 794, no. 1, 25 August 2003 (2003-08-25), pages 115 - 123, XP004441234, ISSN: 1570-0232 *
GYNTHER J: "EI AND CI MASS FRAGMENTATION OF TRYPTAMINE TETRAHYDRO-BETA-CARBOLINE AND SOME OF THEIR DERIVATIVES", ACTA CHEMICA SCANDINAVICA SERIES B ORGANIC CHEMISTRY AND BIOCHEMISTRY, vol. 42, no. 7, 1988, pages 433 - 441, XP009069653, ISSN: 0302-4369 *
KENNAWAY D J ET AL: "A SPECIFIC RADIO IMMUNOASSAY FOR MELATONIN IN BIOLOGICAL TISSUE AND FLUIDS AND ITS VALIDATION BY GAS CHROMATOGRAPHY MASS SPECTROMETRY", ENDOCRINOLOGY, vol. 101, no. 1, 1977, pages 119 - 127, XP009069654, ISSN: 0013-7227 *
LE BARS D ET AL: "[<13>C, <2>H4]melatonin", JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS 1989 UNITED KINGDOM, vol. 27, no. 9, 1989, pages 1101 - 1103, XP009069660, ISSN: 0362-4803 *
LEONE R M ET AL: "MELATONIN CAN BE DIFFERENTIALLY METABOLIZED IN THE RAT TO PRODUCE N ACETYL SEROTONIN IN ADDITION TO 6 HYDROXY MELATONIN", ENDOCRINOLOGY, vol. 114, no. 5, 1984, pages 1825 - 1832, XP009069661, ISSN: 0013-7227 *
SHAW G J ET AL: "Mass spectra of some specifically deuterated tryptamines.", BIOMEDICAL MASS SPECTROMETRY. DEC 1977, vol. 4, no. 6, December 1977 (1977-12-01), pages 348 - 353, XP002391397, ISSN: 0306-042X *
YOUNG I M ET AL: "The mass spectrometric analysis of the urinary metabolites of melatonin and its deuterated analogues, confirming their identity as N-acetylserotonin and 6-hydroxymelatonin.", BIOMEDICAL MASS SPECTROMETRY. JUL 1985, vol. 12, no. 7, July 1985 (1985-07-01), pages 319 - 337, XP002391399, ISSN: 0306-042X *

Also Published As

Publication number Publication date
WO2006086978A2 (de) 2006-08-24
DE102005008312A1 (de) 2006-08-24

Similar Documents

Publication Publication Date Title
IL190150A0 (en) New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of alzheimer&#39;s disease
EG23719A (en) New process for the synthesis of (I S)-4,5-dimethoxy-1-(methylaminomethyl)-benzocyclobutane and addition salts thereof, and application in the synthesis of I V abradine and addition salts thereof witha pharmaceutically acceptable acid
EP2168962A3 (de) Phenylacetamide und ihre Verwendung als Glucokinase-Modulatoren
ZA200802811B (en) Therapy for the treatment of disease
WO2008021113A3 (en) Transdermal methods and systems for treating alzheimer&#39;s disease
WO2007062078A3 (en) Thrombopoietin activity modulating compounds and methods
TW200806318A (en) Uses of anti-insulin-like growth factor I receptor antibodies
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
WO2006086978A3 (de) Verwendung deuterierter n-[2-(5-methoxy-1h-indol-3-yl)-ethyl]acetamide und deren pharmazeutisch verträglicher salze sowie diese verbindungen enthaltende arzneimittel
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
MX2009006742A (es) Inhibidores acilaminopirazoles como fgfr.
ZA200606834B (en) 1-Aminocyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with Alzheimer&#39;s disease
HK1152705A1 (en) Dihydropyrimidine compounds and use thereof for the treatment of viral diseases
UA81573C2 (en) Use of agomelatine for the preparation of medicaments for the treatment of sleep disorders in depressed patients
WO2007016679A3 (en) Combination immediate release controlled release levodopa and carbidopa dosage forms
NZ593467A (en) Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
ATE353645T1 (de) Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia
MXPA05011472A (es) Uso de derivados de azetidincarboxamida en terapia.
WO2008092072A3 (en) Modulators of the metabotropic glutamate receptor subtype 5 and uses thereof
TNSN08506A1 (en) Substituted carboxamides
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
WO2005123068A3 (en) Methods of dealying alzheimer’s disease progression using a beta-amyloid precursor protein inhibitor and a hmg coa reductase inhibitor
WO2005062992A3 (en) Substituted melatonin derivatives, process for their preparation, and methods of use
WO2007047893A3 (en) Use of dasatinib for the treatment of bone metastasis
GB0522908D0 (en) Therapeutic agents

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase

Ref document number: 06722509

Country of ref document: EP

Kind code of ref document: A2

WWW Wipo information: withdrawn in national office

Ref document number: 6722509

Country of ref document: EP